A prospective,open, single-arm clinical study for the efficacy and safety of PD-1 antibody SHR-1210 in combination with apatinib mesylate for EGFR-sensitive mutations and EGFR-TKI treatment failure in advanced non-small cell lung cancer (NSCLC)
Latest Information Update: 25 Jul 2021
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 03 Aug 2020 New trial record